Akeso Biomedical is applying recent breakthroughs in silk technology to develop implants specifically designed to improve wound healing beginning with products for the treatment of venous stasis ulcers. Akeso's proprietary silk implants are being designed to provide scaffolds for tissue in-growth, encourage vascularization, and control bioburden, moisture levels, and the presence of destructive enzymes. The new silk technology provides improvements in processing, yield, and stability, allows the rate of degradation of the silk implant to be fine-tuned to the specific clinical need, as well as delivery of active agents from the implant.
Ascendant Diagnostics is developing innovative new approaches to the improved diagnosis of serious diseases and conditions. Its first product is a non-invasive test for early stage diagnosis of breast cancer. Approximately 240,000 women are diagnosed with breast cancer each year in the U.S. and the total economic burden of treatment is about $40 billion. However, survival rates are greatly enhanced and treatment costs are much lower when breast cancer is treated at an early stage. Improved diagnostic tests that are simple, reliable and non-invasive could save many lives by detecting the breast cancer earlier. Ascendant Diagnostics’ breast cancer detection technology is aimed at this critical unmet need.
The mission of BioDetection Instruments is to improve the safety and quality of the world's food supply by providing the highest performance biosensors, assay kits and instruments for rapid detection of food pathogens and chemical residues. The company’s Aegis™ biosensor system provides an unparalleled combination of low detection limits (down to 10 cells/mL) and speed (1 hour) for the identification and quantification of pathogenic bacteria in food and drinks.
The risk of a woman over the age of fifty dying from an osteoporosis-related fracture is greater than the risk of her dying from breast, uterine, and ovarian cancer combined. BiologicsMD is developing a new prescription osteoporosis solution based on a unique patent-pending compound that binds to bone and stimulates new bone growth thereby reversing osteoporosis. Pre-clinical animal studies demonstrate that it is three times more effective at increasing bone density than the leading medication with no observed side effects. 2008 revenues for prescription osteoporosis medications exceeded $9 billion globally and $2 billion in the U.S.
BlueInGreen offers equipment that incorporates an innovative new approach for cost effective dissolved oxygen delivery. The supersaturated dissolved oxygen (or SDOX™) systems offer low capital and operating costs, precisely controlled delivery of dissolved oxygen at a wide range of target concentrations, ease of operation, and virtually 100% gas utilization efficiency (no off-gassing) for wastewater treatment and other environmental water applications. Up to 80% operating cost savings have been documented as compared to conventional oxygen delivery technology.
Cardiovascular disease is the leading cause of death for men and women in the United States and kills 2,400 Americans every day (1 every 37 seconds). It is estimated that 80,700,000 Americans (1 in 3) have some form of cardiovascular disease. CardioWise is developing new approaches to cardiac health monitoring and care. Its first product is a new cardiac imaging modality that:
▸ Allows all images to be acquired in a single one-hour appointment;
▸ Requires no exposure to intravenous contrast, dobutamine, dipyridamole, or ionizing radiation;
▸ Produces images of cardiac contractile function throughout the thickness of the left ventricle as opposed to just the surface;
▸ Delivers quantitative, detailed, and easily interpreted, color coded images; and
▸ Enables direct, quantified comparison of data from an individual acquired at different times.
NanoMech was the first company formed by VIC. It now operates as a fully independent, rapidly growing company and is a designer and manufacturer of innovative, application specific nanomaterial based products. One of the company's key product lines is based on a patented, award-winning technology that allows very small particles to be applied to surfaces in coating form, creating coatings that have extremely beneficial properties. These nanocoatings can be engineered to have valuable properties such as extreme wear resistance, self-lubrication, corrosion resistance, bio-compatibility, and many other attributes important to a wide range of applications. Some of these applications include hard coatings for cutting tools and wear parts, high-strength ceramics, adaptive coatings for military and industrial applications, improved implant surfaces for medical and dental implants, and other applications.
NanoWatt Design holds exclusive license to a patent-pending asynchronous circuit architecture that promises order-of-magnitude reductions in power consumption of digital circuitry, without sacrificing speed. The new Sleep Convention Logic (SCL) technology is fundamentally delay insensitive, overcoming timing issues with previous asynchronous architectures. In addition, the company will provide designers with software that allows industry-standard tools to be used in creating asynchronous SCL circuits. Overall, the technology is poised to become the most important integrated circuit design breakthrough of the decade.
Nutraceutical Innovations is developing applications of patent pending processes for value-added processing of rice bran and other food sources. The company is developing nutraceutical ingredients such as protein, phenolics and prebiotics that have numerous potential health benefits including antimutagenicity, anti-cancer properties and hypertension reduction.
OsteoVantage is a biotechnology and medical device company that is developing osteoinductive spinal instrumentation to enhance bone formation after spinal fusion surgery. Initial studies have demonstrated both the safety and efficacy of the spinal instrumentation. Future product lines may include osteogenic hardware for long bone repair and electroconductive mesh for facial and skull reconstruction or repair. Bone heals similarly in all animals so at a future point this technology is applicable to both veterinary and human orthopedic surgery.
Sevo Nutraceuticals, Inc. was established in 2012 to license and market science-based nutraceuticals. Its vision is to become a market leader in highly efficacious, scientifically researched nutraceuticals that improve people's lives. The Company's mission is to build a select portfolio of high value products with clear markets which are leaders in their category. Sevo’s cornerstone product, PERCEPTIV™, was licensed from UMass Lowell in 2012 and was developed under the leadership of UMass Lowell Professor Thomas B. Shea, Director, Center for Cellular Neurobiology and Neurodegeneration Research.
SFC Fluidics, LLC has unique product lines that span a diverse range of markets including point-of-care diagnostics, analytical instrumentation and drug delivery. A driving trend in biomedical and analytical instrumentation is toward higher performance, lower operating cost and portability. Our products are based on innovative technologies that improve speed, performance and affordability. The company's mission is to expand scientific knowledge, advance health care, and improve overall quality of life through our enabling microfluidics technologies.
TiFiber produces unique, thermally stable, chemically inert titanium dioxide nanofibers. These inorganic nanofibers can be used in a process analogous to making paper to craft free standing membranes. The free standing membranes possess unique porosity, permeability, thermal stability, chemical inertness, robustness, and catalytic activities, all of which differentiate TiFiber's material from monodispersed nanofibers and nanopowder. TiFiber nanofibers and membranes offer great performance advantages for high temperature filtration, catalysis, sensing, sorption, separation and many other large commercial applications.
Vixiar Medical is developing a portable, non-invasive device that allows remote monitoring of congestive heart failure patients. The proprietary diagnostic technique, licensed from Johns Hopkins University, allows monitoring of patients that have been recently discharged from the hospital for heart failure, for home monitoring of high risk patients by physicians, by “low capability” clinics & nursing homes, and by emergency departments or emergency medical technicians in the field.